UK and USA-based clinical-stage biotech Orchard Therapeutics today announces the appointment of Mark Rothera as president and chief executive.
Mr Rothera brings 28 years of experience in the biopharmaceutical industry including driving the transition of multiple emerging biotechnology companies from R&D stage to commercialization. During his career, he has focused on bringing novel therapies to market for patients with rare diseases, and has launched seven orphan drugs.
Until recently Mr Rothera served as chief commercial officer of PTC Therapeutics, where he helped transition the company from a privately funded, USA-based R&D biotech to a public, commercial stage company with a 47 country commercialization footprint. This he achieved by building a global commercialization capability and successfully launching two rare disease therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze